恒瑞医药(600276.SH)：1类创新药泽美妥司他片获附条件批准上市

Core Viewpoint - Heng Rui Medicine (600276.SH) has received conditional approval from the National Medical Products Administration for its independently developed innovative drug, Zemeituosita Tablets (SHR2554), which is intended for adult patients with relapsed or refractory peripheral T-cell lymphoma (R/RPTCL) who have previously undergone at least one line of systemic therapy [1] Company Summary - Zemeituosita Tablets is the first EZH2 inhibitor independently developed in China [1]